Etbx-051 (Not yet branded)
Other Medications
Description
Etbx-051 is a multi-targeted recombinant adenovirus serotype 5 (Ad5) based immunotherapy vaccine designed to treat advanced colorectal cancer and other solid tumors. This therapeutic vaccine simultaneously targets three tumor-associated antigens: carcinoembryonic antigen (CEA), mucin 1 (MUC1), and brachyury transcription factor, which are commonly overexpressed in colorectal malignancies. The vaccine aims to stimulate the patient's immune system to recognize and attack cancer cells expressing these specific antigens.
Mechanism of Action
Etbx-051 utilizes a replication-defective adenoviral vector to deliver genetic material encoding CEA, MUC1, and brachyury antigens directly to antigen-presenting cells. Upon administration, the vaccine induces both cellular and humoral immune responses, generating cytotoxic T-lymphocytes and antibodies specifically directed against tumor cells expressing these target antigens. This multi-antigen approach is designed to reduce the likelihood of immune escape and enhance overall anti-tumor efficacy.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 Estado EMA | Experimental |
 Acceso España | med_spain_not_available |
| Administration | Intramuscular |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.